Analgesics and Anti-inflammatory Drugs Practice Questions

Q: Which of the following drugs is a selective COX-2 inhibitor?

Etoricoxib. **Explanation:** The correct answer is **Etoricoxib**. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are classified based on their selectivity for the Cyclooxygenase (COX) enzymes. COX-1 is constitutive (protective for gastric mucosa and platelets), while COX-2 is inducible (mediated by inflammation). **Etoricoxib** belongs to the "coxib" class, which are **highly selective COX-2 inhibitors**. These drugs provide potent anti-inflammatory and analgesic effects with a significantly lower risk of gastrointestinal ulcers and bleeding compared to non-selective agents. **Analysis of Incorrect Options:** * **A. Ketorolac:** A potent non-selective NSAID with a high affinity for **COX-1**. It is primarily used for short-term management of severe acute pain but carries a high risk of GI toxicity. * **C. Piroxicam:** An oxicam derivative that is a **non-selective** COX inhibitor with a long half-life. It is associated with a higher incidence of gastric side effects. * **D. Nimesulide:** Classified as a **preferential** COX-2 inhibitor (not highly selective). While it favors COX-2, it still inhibits COX-1 to some degree. **High-Yield Clinical Pearls for NEET-PG:** * **Selectivity Ratio:** Etoricoxib has the highest COX-2 selectivity among the available coxibs (Etoricoxib > Valdecoxib > Celecoxib). * **Cardiovascular Risk:** Selective COX-2 inhibitors lack anti-platelet activity (as they don't inhibit TXA2) and may shift the balance toward pro-thrombotic states, increasing the risk of myocardial infarction and stroke. * **Sulfonamide Allergy:** Celecoxib contains a sulfonamide moiety; use with caution in patients with sulfa allergies. * **Aspirin-Exacerbated Respiratory Disease (AERD):** Selective COX-2 inhibitors are generally safe in patients with "Aspirin Triad" (asthma, nasal polyps, and NSAID sensitivity).

Q: Which opioid drug is administered via the transdermal route?

Fentanyl. **Explanation:** **Fentanyl** is the correct answer because it possesses the ideal physicochemical properties for transdermal delivery: high lipid solubility, low molecular weight, and high potency. The **Fentanyl Transdermal Patch** (Durogesic) utilizes a rate-limiting membrane to provide stable plasma concentrations over 72 hours. It is primarily used for chronic cancer pain and is not suitable for acute or postoperative pain due to its slow onset (12–24 hours to reach peak effect) and long offset. **Analysis of Incorrect Options:** * **A. Sufentanil:** While highly potent and lipid-soluble, it is primarily used intravenously or via the sublingual route (Zalviso) for acute pain. Transdermal formulations exist but are not standard clinical practice compared to Fentanyl. * **B. Remifentanil:** This drug is unique due to its metabolism by **non-specific plasma esterases**, giving it an ultra-short duration of action (half-life <10 mins). It must be given via continuous IV infusion; a transdermal route would defeat the purpose of its rapid titratability. * **C. Alfentanil:** It has a rapid onset and short duration, used mainly for blunting the pressor response to intubation. It is less lipid-soluble than Fentanyl, making it less suitable for transdermal application. **High-Yield Clinical Pearls for NEET-PG:** * **Potency Ratio:** Sufentanil (1000x) > Fentanyl (100x) > Morphine (1x). * **Context-Sensitive Half-Time:** Remifentanil remains constant regardless of infusion duration, whereas Fentanyl increases significantly after long infusions. * **Fentanyl Patch Caution:** Fever or external heat (e.g., heating pads) can increase drug release from the patch, leading to potential overdose/respiratory depression.

Q: Long-term use of aspirin in rheumatoid arthritis is limited by its propensity to cause which of the following?

Gastric mucosal damage. ### Explanation **Correct Answer: C. Gastric mucosal damage** **Mechanism of Action:** Aspirin (Acetylsalicylic acid) is a non-selective inhibitor of the **Cyclooxygenase (COX)** enzymes [3]. In the management of Rheumatoid Arthritis (RA), high anti-inflammatory doses are required [2]. Aspirin inhibits **COX-1**, which is responsible for synthesizing cytoprotective prostaglandins ($PGE_2$ and $PGI_2$) in the gastric mucosa [3]. These prostaglandins normally inhibit gastric acid secretion and promote mucus/bicarbonate production. Their depletion leads to increased acid damage, erosions, and peptic ulcers, making gastric intolerance the most common dose-limiting side effect in long-term therapy [1]. **Analysis of Incorrect Options:** * **A. Metabolic acidosis:** This is a feature of **acute salicylate poisoning** (toxic doses), not typical long-term therapeutic use. In adults, it is usually preceded by respiratory alkalosis. * **B. Hypersensitivity reactions:** While serious (e.g., Aspirin-Exacerbated Respiratory Disease), these are idiosyncratic and occur in a small percentage of the population, rather than being a dose-dependent limitation for most RA patients [2]. * **D. Salicylism:** This is a syndrome of mild toxicity (tinnitus, dizziness, headache). While it occurs with high doses, gastric distress usually manifests earlier and more frequently in chronic management [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Zero-order kinetics:** At anti-inflammatory doses (high doses), aspirin follows capacity-limited elimination. * **Samter’s Triad:** Aspirin sensitivity, Bronchial Asthma, and Nasal polyps. * **Reye’s Syndrome:** Aspirin is contraindicated in children with viral infections (Varicella/Influenza) due to the risk of hepatic encephalopathy. * **Anti-platelet effect:** Occurs at low doses (75–150 mg) via irreversible inhibition of COX-1 in platelets (thromboxane $A_2$ reduction) [3].

Q: Which of the following is the longest-acting NSAID?

Piroxicam. **Explanation:** The correct answer is **Piroxicam**. The duration of action of an NSAID is primarily determined by its **plasma half-life ($t_{1/2}$)**. Piroxicam belongs to the **Oxicam** derivative class and is characterized by an exceptionally long half-life of approximately **45–50 hours**. This pharmacological profile allows for **once-daily dosing**, which significantly improves patient compliance in chronic conditions like rheumatoid arthritis and osteoarthritis. **Analysis of Incorrect Options:** * **Aspirin:** It has a very short plasma half-life (approx. 15–20 minutes) because it is rapidly hydrolyzed to salicylic acid. Even its active metabolite, salicylate, has a dose-dependent half-life (3–15 hours), which is much shorter than Piroxicam. * **Ibuprofen:** A propionic acid derivative with a short half-life of about **2 hours**. It requires frequent dosing (3–4 times daily) to maintain therapeutic levels. * **Acetaminophen (Paracetamol):** While technically an antipyretic-analgesic with weak anti-inflammatory action, its half-life is also short, typically **2–3 hours**. **High-Yield Clinical Pearls for NEET-PG:** * **Longest-acting NSAID:** Piroxicam (Half-life ~50 hours). * **Shortest-acting NSAID:** Aspirin or Diclofenac (Half-life ~1–2 hours). * **Oxicam class:** Includes Tenoxicam (even longer half-life than Piroxicam, ~70 hours, but Piroxicam is the standard exam answer) and Meloxicam (preferential COX-2 inhibitor). * **Side Effect Profile:** Due to its long half-life and enterohepatic recirculation, Piroxicam is associated with a higher risk of **gastric mucosal ulceration** and GI bleeding compared to shorter-acting agents.

Q: What is the most important side effect of aspirin?

Gastritis. **Explanation:** **Aspirin (Acetylsalicylic acid)** is a non-selective, irreversible inhibitor of Cyclooxygenase (COX-1 and COX-2) enzymes. **Why Gastritis is the correct answer:** The most frequent and clinically significant side effect of aspirin is **gastric mucosal damage (Gastritis/Peptic Ulcers)**. This occurs via two mechanisms: 1. **Systemic effect:** Inhibition of COX-1 reduces the synthesis of protective prostaglandins (PGE2 and PGI2), which are essential for maintaining the gastric mucosal barrier, secreting bicarbonate, and regulating blood flow. 2. **Local effect:** Aspirin is an organic acid; it causes direct chemical irritation to the gastric epithelium and can lead to "ion trapping" within mucosal cells, causing cellular damage. **Analysis of Incorrect Options:** * **B. Edema:** While NSAIDs can cause sodium and water retention by inhibiting renal prostaglandins, this is less common with aspirin compared to drugs like Piroxicam or Indomethacin. * **C. Kidney damage:** Chronic use can lead to analgesic nephropathy (papillary necrosis), but this is typically a long-term complication rather than the "most important" or most common acute side effect. * **D. Hypersensitivity:** This manifests as "Aspirin-exacerbated respiratory disease" (Aspirin Asthma) due to a shift in arachidonic acid metabolism toward the leukotriene pathway. While serious, it occurs only in susceptible individuals (approx. 10% of asthmatics). **High-Yield Clinical Pearls for NEET-PG:** * **Reye’s Syndrome:** Aspirin is contraindicated in children with viral infections (Varicella/Influenza) due to the risk of hepatic encephalopathy. * **Salicylism:** Toxicity presents with **Tinnitus** (earliest sign), vertigo, and respiratory alkalosis. * **Antiplatelet action:** Aspirin irreversibly inhibits COX-1 in platelets for their entire lifespan (8–11 days). * **Zero-order kinetics:** Aspirin follows zero-order elimination at high/toxic doses.

Q: Rofecoxib as compared to indomethacin is:

Less likely to cause gastric ulcer and their complications. The core concept behind this question is the **selectivity of COX inhibition**. **1. Why Option A is correct:** Indomethacin is a non-selective NSAID that inhibits both COX-1 and COX-2 enzymes. COX-1 is "constitutive" and responsible for producing cytoprotective prostaglandins ($PGE_2$ and $PGI_2$) in the gastric mucosa. Inhibiting COX-1 leads to gastric erosions and ulcers. **Rofecoxib** is a **selective COX-2 inhibitor** [1, 3]. Since COX-2 is primarily induced at sites of inflammation, sparing COX-1 allows the gastric mucosal barrier to remain intact, significantly reducing the risk of GI ulcers and bleeding compared to non-selective agents like indomethacin [1, 3]. **2. Why other options are incorrect:** * **Option B:** Selective COX-2 inhibitors are **equally effective**, but not superior, to non-selective NSAIDs in managing pain and inflammation in rheumatoid arthritis. Their advantage is safety (GI profile), not increased efficacy [1, 3]. * **Option C:** Both COX-1 and COX-2 are expressed in the kidneys. Therefore, selective COX-2 inhibitors like Rofecoxib **can still cause renal complications** (e.g., edema, hypertension, and renal failure) similar to traditional NSAIDs [1, 2]. **High-Yield Clinical Pearls for NEET-PG:** * **The "Coxib" Paradox:** While Rofecoxib is GI-friendly, it was withdrawn globally (VIGOR study) because it increases the risk of **myocardial infarction and stroke** [1, 2, 3]. This is due to the suppression of vascular $PGI_2$ (vasodilator/anti-aggregatory) without affecting Thromboxane $A_2$ (vasoconstrictor/pro-aggregatory). * **Drug of Choice:** Indomethacin remains the drug of choice for **Ankylosing Spondylitis** and **Patent Ductus Arteriosus (PDA)**. * **Key Contraindication:** Avoid selective COX-2 inhibitors in patients with established ischemic heart disease [2, 3].

Q: Which of the following opioid analgesics acts primarily through mu opioid receptors?

Pentazocine. The question asks for an opioid that acts **primarily** through mu (μ) receptors. However, there appears to be a discrepancy in the provided key: **Pentazocine** is actually a **kappa (κ) receptor agonist** and a weak mu (μ) receptor antagonist/partial agonist. In standard pharmacological classification, **Methadone** and **Pethidine** are pure mu-agonists [1], while **Buprenorphine** is a partial mu-agonist [1]. If we follow the provided key (A), it is important to note that Pentazocine is the prototype of **agonist-antagonist** opioids. Pentazocine (Correct per key): It acts as an agonist at **kappa (κ) receptors** (mediating spinal analgesia and dysphoria) and has weak antagonistic or partial agonistic activity at **mu (μ) receptors**. It is unique because it can precipitate withdrawal in opioid-dependent individuals. **Methadone (Incorrect):** A potent, long-acting **pure mu-receptor agonist** [1]. It is primarily used in the management of opioid withdrawal and maintenance therapy due to its long half-life and minimal withdrawal symptoms. **Buprenorphine (Incorrect):** A **partial mu-agonist** and kappa-antagonist. It has a high affinity for mu receptors but low intrinsic activity (ceiling effect for respiratory depression) [1]. **Pethidine (Meperidine) (Incorrect):** A **pure mu-agonist** [1]. It is notable for its metabolite, *normeperidine*, which can cause seizures, and its lack of miosis (it causes mydriasis due to atropine-like action). **High-Yield Clinical Pearls for NEET-PG:** 1. **Pentazocine Side Effects:** Characterized by "psychotomimetic" effects (hallucinations, dysphoria) due to kappa stimulation. 2. **Pethidine:** Preferred in biliary colic (less sphincter of Oddi spasm than Morphine) and for shivering. 3. **Buprenorphine:** Used in "Office-based" opioid detoxification; its effects are not easily reversed by Naloxone due to slow receptor dissociation [1].

Q: Which of the following is not a DMARD in the treatment of rheumatoid arthritis?

Corticosteroids. **Explanation:** The core concept in treating Rheumatoid Arthritis (RA) is the distinction between drugs that provide symptomatic relief and those that modify the disease process. **Disease-Modifying Anti-Rheumatic Drugs (DMARDs)** are agents that slow down disease progression, prevent joint destruction, and reduce radiological damage. **Why Corticosteroids is the correct answer:** While corticosteroids (like Prednisolone) are potent anti-inflammatory agents used to provide rapid symptomatic relief and "bridge" the gap until DMARDs become effective, they are **not** classified as DMARDs. They do not fundamentally arrest the long-term progression of the disease or prevent joint deformity when used alone. Chronic use is also limited by significant systemic toxicity. **Analysis of incorrect options:** * **A. Methotrexate:** The "Gold Standard" and first-line DMARD. It acts by inhibiting dihydrofolate reductase and increasing adenosine levels, which suppresses inflammation and joint damage. * **B. Leflunomide:** A prodrug that inhibits the enzyme dihydroorotate dehydrogenase, leading to decreased pyrimidine synthesis. It is a potent DMARD often used as an alternative to Methotrexate. * **D. Penicillamine:** A conventional (synthetic) DMARD. Though rarely used today due to toxicity (like proteinuria and myasthenia-like syndrome), it historically belongs to the DMARD category. **High-Yield Clinical Pearls for NEET-PG:** * **Classification:** DMARDs are divided into **csDMARDs** (Conventional Synthetic: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide) and **bDMARDs** (Biologicals: TNF-inhibitors like Etanercept, Infliximab). * **Fastest acting DMARD:** Sulfasalazine. * **Slowest acting DMARD:** Hydroxychloroquine (takes 3–6 months). * **Methotrexate Monitoring:** Requires supplementation with Folic acid to reduce GI and mucosal side effects. It is contraindicated in pregnancy (Teratogenic).

Q: Which drug is used for the treatment of acute gout?

Indomethacin. **Explanation:** The primary goal in treating **acute gout** is to control pain and inflammation. **Indomethacin**, a potent Non-Steroidal Anti-inflammatory Drug (NSAID), is the traditional drug of choice for acute attacks. It works by inhibiting cyclooxygenase (COX) enzymes, thereby reducing the synthesis of prostaglandins that mediate pain and swelling in the joint. **Analysis of Options:** * **Indomethacin (Correct):** It is highly effective in terminating an acute gouty attack. Other NSAIDs like Naproxen or Diclofenac are also used, but Indomethacin remains the classic textbook answer. * **Aspirin (Incorrect):** Aspirin is contraindicated in gout. At low doses, it inhibits the tubular secretion of uric acid, leading to **hyperuricemia**, which can worsen or prolong an attack. * **Allopurinol & Febuxostat (Incorrect):** These are **hypouricemic agents** (Xanthine Oxidase Inhibitors) used for **chronic gout** (prophylaxis). They should never be started during an acute attack because a rapid drop in serum urate levels can cause the mobilization of urate crystals from tissues, paradoxically worsening the acute inflammation. **High-Yield Clinical Pearls for NEET-PG:** * **First-line for Acute Gout:** NSAIDs (e.g., Indomethacin) are first-line. If NSAIDs are contraindicated (e.g., peptic ulcer, renal failure), **Colchicine** or **Glucocorticoids** are used. * **Colchicine Mechanism:** It inhibits microtubule assembly by binding to tubulin, thereby preventing neutrophil migration to the joint. * **The "Wait" Rule:** Never start or stop Allopurinol during an acute attack. Wait 2–4 weeks after the attack has subsided before initiating urate-lowering therapy.

Q: Cyclosporine inhibits which of the following?

T lymphocyte proliferation. **Explanation:** **Mechanism of Action (Why A is correct):** Cyclosporine is a potent **calcineurin inhibitor**. Under normal physiological conditions, an increase in intracellular calcium activates calcineurin (a phosphatase). Calcineurin then dephosphorylates the **Nuclear Factor of Activated T-cells (NFAT)**, allowing it to enter the nucleus and initiate the transcription of **Interleukin-2 (IL-2)**. IL-2 is the primary cytokine responsible for the proliferation and differentiation of T lymphocytes. By binding to cyclophilin, Cyclosporine forms a complex that inhibits calcineurin, thereby blocking IL-2 production and specifically halting **T lymphocyte proliferation**. **Analysis of Incorrect Options:** * **Option B & C:** Cyclosporine is highly selective for T-cells. It does not significantly inhibit B lymphocyte proliferation directly, as B-cell activation involves different signaling pathways that are less dependent on the calcineurin-NFAT axis. * **Option D:** While Cyclosporine may have minor downstream effects on the immune cascade, its primary and therapeutic target is the T-helper cell (CD4+), not Natural Killer (NK) cells. **High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Uses:** Prevention of graft-versus-host disease (GVHD) in organ transplants and treatment of autoimmune conditions like rheumatoid arthritis and psoriasis. * **Adverse Effects (The "H" Mnemonic):** **H**ypertension, **H**yperplasia of gums (gingival hyperplasia), **H**irsutism, and **H**yperkalemia. * **Most Serious Side Effect:** Nephrotoxicity (dose-related and usually reversible). * **Metabolism:** It is metabolized by **CYP3A4**; therefore, grapefruit juice (an inhibitor) can increase its toxicity.

Question 1

Which of the following drugs is a selective COX-2 inhibitor?

Accepted Answer

Etoricoxib

Answer

Ketorolac

Answer

Piroxicam

Answer

Nimesulide

Question 2

Which opioid drug is administered via the transdermal route?

Accepted Answer

Fentanyl

Answer

Sulfentanil

Answer

Remifentanil

Answer

Alfentanil

Question 3

Long-term use of aspirin in rheumatoid arthritis is limited by its propensity to cause which of the following?

Accepted Answer

Gastric mucosal damage

Answer

Metabolic acidosis

Answer

Hypersensitivity reactions

Answer

Salicylism

Question 4

Which of the following is the longest-acting NSAID?

Accepted Answer

Piroxicam

Answer

Aspirin

Answer

Ibuprofen

Answer

Acetaminophen

Question 5

What is the most important side effect of aspirin?

Accepted Answer

Gastritis

Answer

Edema

Answer

Kidney damage

Answer

Hypersensitivity

Question 6

Rofecoxib as compared to indomethacin is:

Accepted Answer

Less likely to cause gastric ulcer and their complications

Answer

Likely to be more effective in rheumatoid arthritis

Answer

Not likely to produce renal complications

Answer

All of the above

Question 7

Which of the following opioid analgesics acts primarily through mu opioid receptors?

Accepted Answer

Pentazocine

Answer

Methadone

Answer

Buprenorphine

Answer

Pethidine

Question 8

Which of the following is not a DMARD in the treatment of rheumatoid arthritis?

Accepted Answer

Corticosteroids

Answer

Methotrexate

Answer

Leflunomide

Answer

Penicillamine

Question 9

Which drug is used for the treatment of acute gout?

Accepted Answer

Indomethacin

Answer

Aspirin

Answer

Febuxostat

Answer

Allopurinol

Question 10

Cyclosporine inhibits which of the following?

Accepted Answer

T lymphocyte proliferation

Answer

B lymphocyte proliferation

Answer

Both T and B lymphocyte proliferation

Answer

NK cells only

Analgesics and Anti-inflammatory Drugs — MCQs

Analgesics and Anti-inflammatory Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?